Novavax Q1 revenue $140M, net loss $9M; Pfizer Matrix-M deal adds $30M upfront

NOVAVAX INC

2026-Q1 EPS reported -$0.06 revenue$139,514,000

Total revenue $140M, down 79% YoY; prior-year included $603M non-cash APA close-out.
Net loss $9M vs net income $519M in Q1 2025; cash $795M, up from $751M.
Pfizer non-exclusive Matrix-M license yielded $30M upfront, potential milestones up to $500M.
Matrix-M partnering expanded: four top-10 pharma companies exploring over 30 fields; new MTAs signed.
FY 2026 guidance reiterated: Non-GAAP combined R&D+SG&A $310-340M; cash position strengthened by $330M credit facility.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

NOVAVAX INC reported the first quarter ended March 31, 2026 results: revenue Total revenue of $140 million in the first quarter of 2026. Guidance reaffirmed.

Period: the first quarter ended March 31, 2026
Revenue: Total revenue of $140 million in the first quarter of 2026
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Novavax Reports First Quarter 2026 Financial Results and Operational Highlights • Total revenue of $140 million in the first quarter of 2026

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

NOVAVAX INC filing history →

Source: SEC EDGAR

accession 0001628280-26-030924

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.